ArticleACS omega2026
Fine-Tuning DeepSeek-OCR‑2 for Molecular Structure Recognition.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
Abstract
Optical chemical structure recognition (OCSR) is critical for converting 2D molecular diagrams from printed literature into machine-readable formats. While vision-language models have shown promise in end-to-end OCR tasks, their direct application to OCSR remains challenging, and direct full-parameter supervised fine-tuning often fails. In this work, we adapt DeepSeek-OCR-2 for molecular optical recognition by formulating the task as an image-conditioned SMILES generation. To overcome training instabilities, we propose a two-stage progressive supervised fine-tuning strategy: starting with parameter-efficient LoRA and transitioning to selective full-parameter fine-tuning with split learning rates. We train our model on a large-scale corpus combining synthetic renderings from PubChem and realistic patent images from USPTO-MOL to improve the coverage and robustness. Our fine-tuned model, MolSeek-OCR, demonstrates competitive capabilities, achieving exact-match accuracies comparable to those of the best-performing image-to-sequence model. However, it remains inferior to state-of-the-art image-to-graph models. Exploratory post-training shows mixed results: ReFT provides small benchmark-dependent gains, whereas GSPO does not yield stable improvement and can collapse under extended optimization.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.